Theravance Biopharma, Inc.
NASDAQ:TBPHBiotechnology
-$0.07 today
- Market cap
- $882.64M
- Beta
- 0.18
- P/E (TTM)
- 7.4
- EPS (TTM)
- $2.23
Volume 10.02M
Average 0.43M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Theravance Biopharma, Inc.
NASDAQ:TBPH
Intrinsic Alpha fair value
Locked
Current Price
$17.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | -4.5% (5yr)1 analysts |
| Revenue | N/A | N/A | +27.9% | +1.2% (5yr)2 analysts |
| Net Income | N/A | N/A | -50.5% | -4.4% (5yr)2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +27.9% over three years. Forward estimates point to Revenue at +1.2% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Vir Biotechnology, Inc. NASDAQ:VIR | $1.80B | $10.66 | Not rated | -3.0 | +59.53% |
ArriVent BioPharma, Inc. Common Stock NASDAQ:AVBP | $1.33B | $28.45 | Not rated | -9.8 | -43.87% |
Tyra Biosciences, Inc. NASDAQ:TYRA | $1.30B | $21.76 | Not rated | -13.4 | -6.05% |
Replimune Group, Inc. NASDAQ:REPL | $1.04B | $12.36 | Not rated | -3.0 | +113.43% |
Monte Rosa Therapeutics, Inc. NASDAQ:GLUE | $994.32M | $11.77 | Not rated | -9.1 | -34.10% |
Geron Corporation NASDAQ:GERN | $808.32M | $1.26 | Not rated | -12.3 | -17.00% |
Valneva SE NASDAQ:VALN | $582.22M | $6.14 | Not rated | -2.9 | -37.10% |
LENZ Therapeutics, Inc. NASDAQ:LENZ | $122.75M | $3.92 | Not rated | -1.7 | -87.95% |
Continue the stock analysis
Jump to another research area for this company.